Skip to main content
SpringerLink
Log in

Radiotherapy

Radioactive somatostatin analog therapy against carcinoids

  • News & Views
  • Published:

From Nature Reviews Endocrinology

View current issue Sign up to alerts

    We’re sorry, something doesn't seem to be working properly.

    Please try refreshing the page. If that doesn't work, please contact support so we can address the problem.

A recent article by Bushnell et al. confirms and reassures what neuroendocrine tumor specialists have witnessed and believed for some time: radionuclide therapy using somatostatin analogs labeled with radioactive yttrium-90 alleviates symptoms of metastatic neuroendocrine tumors, reduces or stabilizes tumor burden and improves quality of life.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Bushnell, D. L. et al. 90Y-edotreotide for metastatic carcinoid refractory to octreotide. J. Clin. Oncol. 28, 1652–1659 (2010).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Van Essen, M., Krenning, E. P., De Jong, M., Valkema, R. & Kwekkeboom, D. J. Peptide receptor radionuclide therapy with radiolabeled somatostatin analogs in patients with somatostatin receptor positive tumors. Acta Oncol. 46, 723–734 (2007).

    Article  CAS  PubMed  Google Scholar 

  3. Warner, R. R. Carcinoid case presentation and discussion: the American perspective. Endocr. Relat. Cancer. 10, 489–496 (2003).

    Article  CAS  PubMed  Google Scholar 

  4. Kvols, L. K. Revisiting C. G. Moertel's land of small tumors. J. Clin. Oncol. 26, 5005–5007 (2008).

    Article  PubMed  Google Scholar 

  5. Oberg, K. Interferon in the management of neuroendocrine GEP-tumors: a review. Digestion 62 (Suppl. 1), 92–97 (2000).

    Article  CAS  PubMed  Google Scholar 

  6. Chan, J. A. & Kulke, M. H. Progress in the treatment of neuroendocrine tumors. Curr. Oncol. Rep. 11, 193–199 (2009).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Phan, A. T. & Yao, J. C. Neuroendocrine tumors: novel approaches in the age of targeted therapy. Oncology 22, 1617–1623 (2008).

    PubMed  Google Scholar 

  8. Kwekkeboom, D. J. et al. Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival. J. Clin. Oncol. 26, 2124–2130 (2008).

    Article  CAS  PubMed  Google Scholar 

  9. Delpassand, E. S. et al. Safety and efficacy of radionuclide therapy with high-activity In-111 pentetreotide in patients with progressive neuroendocrine tumors. Cancer Biother. Radiopharm. 23, 292–300 (2008).

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Endocrinology and Carcinoid and Neuroendocrine Tumor Center, Cedars-Sinai Medical Center, B-131, 8700 Beverly Boulevard, Los Angeles, 90048, CA, USA

    Run Yu

Authors
  1. Run Yu
    View author publications

    You can also search for this author in PubMed Google Scholar

Ethics declarations

Competing interests

The author declares no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Yu, R. Radioactive somatostatin analog therapy against carcinoids. Nat Rev Endocrinol 6, 428–430 (2010). https://doi.org/10.1038/nrendo.2010.94

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrendo.2010.94

  • Springer Nature Limited

Search

Navigation